Migrastatics—anti-Metastatic and Anti-invasion Drugs: Promises and Challenges

Aneta Gandalovičová; Daniel Rosel; Michael Fernandes; Pavel Veselý; Petr Heneberg; Vladimír Čermák; Luboš Petruželka; Sunil Kumar; Victoria Sanz-Moreno; Jan Brábek

doi:10.1016/j.trecan.2017.04.008

Migrastatics—anti-Metastatic and Anti-invasion Drugs: Promises and Challenges

Aneta Gandalovičová, Daniel Rosel, Michael Fernandes, Pavel Veselý, Petr Heneberg, Vladimír Čermák, Luboš Petruželka, Sunil Kumar, Victoria Sanz-Moreno, Jan Brábek

Research output: Contribution to journal › Article › peer-review

271 Citations (Scopus)

275 Downloads (Pure)

Abstract

In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term ‘migrastatics’ for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.

Original language	English
Pages (from-to)	391-406
Journal	Trends in Cancer
Volume	3
Issue number	6
DOIs	https://doi.org/10.1016/j.trecan.2017.04.008
Publication status	E-pub ahead of print - 20 May 2017

Keywords

solid cancer
metastasis
invasion
treatment
contractility
migrastatics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.trecan.2017.04.008Licence: CC BY

Migrastatics—anti-Metastatic and_GANDALOVICOVA_Publishedonline20May2017_GOLD VoR (CC BY)Final published version, 2.95 MBLicence: CC BY

Cite this

@article{60d11e097ab548df9faf374f2ba477d1,

title = "Migrastatics—anti-Metastatic and Anti-invasion Drugs: Promises and Challenges",

abstract = "In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term {\textquoteleft}migrastatics{\textquoteright} for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.",

keywords = "solid cancer, metastasis, invasion, treatment, contractility, migrastatics",

author = "Aneta Gandalovi{\v c}ov{\'a} and Daniel Rosel and Michael Fernandes and Pavel Vesel{\'y} and Petr Heneberg and Vladim{\'i}r {\v C}erm{\'a}k and Lubo{\v s} Petru{\v z}elka and Sunil Kumar and Victoria Sanz-Moreno and Jan Br{\'a}bek",

year = "2017",

month = may,

day = "20",

doi = "10.1016/j.trecan.2017.04.008",

language = "English",

volume = "3",

pages = "391--406",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Migrastatics—anti-Metastatic and Anti-invasion Drugs

T2 - Promises and Challenges

AU - Gandalovičová, Aneta

AU - Rosel, Daniel

AU - Fernandes, Michael

AU - Veselý, Pavel

AU - Heneberg, Petr

AU - Čermák, Vladimír

AU - Petruželka, Luboš

AU - Kumar, Sunil

AU - Sanz-Moreno, Victoria

AU - Brábek, Jan

PY - 2017/5/20

Y1 - 2017/5/20

N2 - In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term ‘migrastatics’ for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.

AB - In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term ‘migrastatics’ for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.

KW - solid cancer

KW - metastasis

KW - invasion

KW - treatment

KW - contractility

KW - migrastatics

U2 - 10.1016/j.trecan.2017.04.008

DO - 10.1016/j.trecan.2017.04.008

M3 - Article

SN - 2405-8033

VL - 3

SP - 391

EP - 406

JO - Trends in Cancer

JF - Trends in Cancer

IS - 6

ER -

Migrastatics—anti-Metastatic and Anti-invasion Drugs: Promises and Challenges

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this